Personalized RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer

In a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, the authors synthesized mRNA neoantigen vaccines in real time from surgically resected pancreatic ductal adenocarcinoma tumors.